The cellular mechanism of action of tedisamil (KC-8857) (TED), a novel antiarrhythmic/antifibrillatory compound, was studied on transmembrane currents in guinea pig, rabbit and dog ventricular myocytes by applying the patch-clamp and the conventional microelectrode technique. In guinea pig myocytes the rapid component of the delayed rectifier potassium current (IKr) was largely diminished by 1 microM TED (from 0.88+/-0.17 to 0.23+/-0.07 pA/pF, n=5, p<0.05), while its slow component (IKs) was reduced only by 5 microM TED (from 8.1+/-0.3 to 4.23+/-0.07 pA/pF, n=5, p<0.05). TED did not significantly change the IKr and IKs kinetics. In rabbit myocytes 1 microM TED decreased the amplitude of the transient outward current (I(to)) from 20.3+/-4.9 to 13.9+/-2.8 pA/pF (n=5, p<0.05), accelerated its fast inactivation time constant from 8.3+/-0.6 to 3.5+/-0.5 ms (n=5, p<0.05) and reduced the ATP-activated potassium current (IKATP) from 38.2+/-11.8 to 18.4+/-4.7 pA/pF (activator: 50 microM cromakalim; n=5, p<0.05). In dog myocytes 2 microM TED blocked the fast sodium current (INa) with rapid onset and moderately slow offset kinetics, while the inward rectifier potassium (IK1), the inward calcium (ICa) and even the I(to) currents were not affected by TED in concentration as high as 10 microM. The differences in I(to) responsiveness between dog and rabbit are probably due to the different alpha-subunits of I(to) in these species. It is concluded that inhibition of several transmembrane currents, including IKr, IKs, I(to), IKATP and even INa, can contribute to the high antiarrhythmic/antifibrillatory potency of TED, underlying predominant Class III combined with I A/B type antiarrhythmic characteristics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/0929867043363631 | DOI Listing |
Am J Cardiovasc Drugs
July 2023
Department of Emergency Medicine, ASUFC Community Hospital of Latisana, Latisana, Italy.
Purpose: Since atrial fibrillation (AF) is one of the major arrhythmias managed in hospitals worldwide, it has a major impact on public health. The guidelines agree on the desirability of cardioverting paroxysmal AF episodes. This meta-analysis aims to answer the question of which antiarrhythmic agent is most effective in cardioverting a paroxysmal AF.
View Article and Find Full Text PDFFront Cardiovasc Med
April 2022
Department of Cardiology, Third Xiangya Hospital, Central South University, Changsha, China.
Background: Whether early pharmacologic cardioversion is necessary for recent-onset atrial fibrillation is still controversial. Current meta-analyses were limited to evaluating the effects within 24 h without sufficient considering longer follow-up outcomes. We aimed to compare the effect of early pharmacologic cardioversion and non-early cardioversion in patients with recent-onset atrial fibrillation within 4-weeks of follow-up.
View Article and Find Full Text PDFAnn Emerg Med
July 2020
Department of Emergency Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY; Department of Emergency Medicine, Kings County Hospital Center, Brooklyn, NY.
Study Objective: We conduct a systematic review and Bayesian network meta-analysis to indirectly compare and rank antidysrhythmic drugs for pharmacologic cardioversion of recent-onset atrial fibrillation and atrial flutter in the emergency department (ED).
Methods: We searched MEDLINE, EMBASE, and Web of Science from inception to March 2019, limited to human subjects and English language. We also searched for unpublished data.
Am J Physiol Heart Circ Physiol
February 2020
Department of Mathematics and Statistics and Neuroscience Institute, Georgia State University, Atlanta, Georgia.
The β-adrenergic regulation of cardiac myocyte contraction plays an important role in regulating heart function. Activation of this system leads to an increased heart rate and stronger myocyte contraction. However, chronic stimulation of the β-adrenergic signaling system can lead to cardiac hypertrophy and heart failure.
View Article and Find Full Text PDFExpert Opin Investig Drugs
August 2009
University Department of Medicine, Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK.
Background: Even established and effective antiarrhythmic drugs (AADs) in atrial fibrillation (AF) are limited by their pro-arrhythmic and non-target organ side effects. Therefore the search continues for safer and effective new AADs.
Objective: This review will examine a novel AAD, tedisamil--a multichannel potassium channel blocker--and its antiarrhythmic properties, focusing on AF.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!